常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.81/-0.91
|
|
企業價值
93.65M
|
| 資產負債 |
|
每股賬面淨值
1.28
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
26.03M
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2025/11/16 08:35 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174. |

2.12 
